Readout Capital
Washington D.C.readoutcap.com
Overview
Readout Capital is a biotechnology-focused investment firm that employs a long/short equity strategy, conducting fundamental research to invest in both public and private life sciences companies.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Epicrispr Biotechnologies | Aug 2026 | Series C | Co-investor |
Key People
James Dahlman
Chief Scientific Officer
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
See something wrong or outdated?